These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38795961)

  • 41. The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data.
    Jensen CE; Sørensen SS; Gudex C; Jensen MB; Pedersen KM; Ehlers LH
    Appl Health Econ Health Policy; 2021 Jul; 19(4):579-591. PubMed ID: 33527304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An EQ-5D-5L Value Set for Belgium.
    Bouckaert N; Cleemput I; Devriese S; Gerkens S
    Pharmacoecon Open; 2022 Nov; 6(6):823-836. PubMed ID: 35927410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimating an EQ-5D-Y-3L Value Set for Indonesia by Mapping the DCE onto TTO Values.
    Fitriana TS; Roudijk B; Purba FD; Busschbach JJV; Stolk E
    Pharmacoeconomics; 2022 Dec; 40(Suppl 2):157-167. PubMed ID: 36348155
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EQ-5D-5L Health-State Values for the Mexican Population.
    Gutierrez-Delgado C; Galindo-Suárez RM; Cruz-Santiago C; Shah K; Papadimitropoulos M; Feng Y; Zamora B; Devlin N
    Appl Health Econ Health Policy; 2021 Nov; 19(6):905-914. PubMed ID: 34173957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
    Gandhi M; Rand K; Luo N
    Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Valuation of the EQ-5D-3L in Russia.
    Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
    Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. German Value Set for the EQ-5D-5L.
    Ludwig K; Graf von der Schulenburg JM; Greiner W
    Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study.
    Al Sayah F; Johnson JA; Ohinmaa A; Xie F; Bansback N;
    Qual Life Res; 2017 Jun; 26(6):1483-1492. PubMed ID: 28124280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Valuation of multi-dimensional health states with a "bolt-on": is there a shortcut?
    Yang Z; Rand K; Luo N
    Value Health; 2024 Jul; ():. PubMed ID: 38977194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
    Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
    Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Graczyk K; Niewada M
    Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
    Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
    Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Valuation of EQ-5D-5L health states from cancer patients' perspective: a feasibility study.
    Chai Q; Yang Z; Liu X; An D; Du J; Ma X; Rand K; Wu B; Luo N
    Eur J Health Econ; 2023 Oct; ():. PubMed ID: 37837519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate Health State Values in the United Arab Emirates.
    Papadimitropoulos EA; Elbarazi I; Blair I; Katsaiti MS; Shah KK; Devlin NJ
    Value Health Reg Issues; 2015 Sep; 7():34-41. PubMed ID: 29698150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
    Karim S; Craig BM; Groothuis-Oudshoorn CGM
    Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: Whose fault is it?
    Yang Z; van Busschbach J; Timman R; Janssen MF; Luo N
    PLoS One; 2017; 12(9):e0184883. PubMed ID: 28934266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Testing the "Nonstopping" Time Trade-Off: Is It Better Than the Composite Time Trade-Off?
    Luo N; Augestad L; Rand K
    Value Health; 2020 Nov; 23(11):1489-1496. PubMed ID: 33127020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
    Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
    Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.